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Objectives: To identify predictors of mortality within
1 year after primary surgery for ovarian cancer.
Design: Prospective nationwide cohort study from
1 January 2005 to 31 December 2012.
Setting: Evaluation of data from the Danish
Gynaecology Cancer Database and the Danish Civil
Registration System.
Participants: 2654 women who underwent surgery
due to a diagnosis of primary ovarian cancer.
Outcome measures: Overall survival and predictors
of mortality within 0–180 and 181–360 days after the
primary surgery. Examined predictors were age,
preoperative American Society of Anesthesiologists
(ASA) score, body mass index (BMI), International
Federation of Gynaecology and Obstetrics (FIGO) stage,
residual tumour tissue after surgery, perioperative
blood transfusion and calendar year of surgery.
Results: The overall 1-year survival was 84%. Within
0–180 days after surgery, the 3 most important
predictors of mortality from the multivariable model
were residual tumour tissue >2 cm versus no residual
tumour (HR=4.58 (95% CI 3.20 to 6.59)), residual
tumour tissue ≤2 cm versus no residual tumour
(HR=2.50 (95% CI 1.63 to 3.82)) and age >64 years
versus age ≤64 years (HR=2.33 (95% CI 1.69 to
3.21)). Within 181–360 days after surgery, FIGO stages
III–IV versus I–II (HR=2.81 (95% CI 1.75 to 4.50)),
BMI<18.5 vs 18.5–25 kg/m2 (HR=2.08 (95% CI 1.18
to 3.66)) and residual tumour tissue >2 cm versus no
residual tumour (HR=1.84 (95% CI 1.25 to 2.70)) were
the 3 most important predictors.
Conclusions: The most important predictors of
mortality within 1 year after surgery were residual
tumour tissue (0–180 days after surgery) and
advanced FIGO stage (181–360 days after surgery).
However, our results suggest that the surgeon should
not just aim at radical surgery, but also pay special
attention to comorbidity, nutritional state, age
>64 years and the need for perioperative blood
transfusion.
INTRODUCTION
Five-year survival is a traditional measure of
the survival of patients with cancer. The
majority (70–80%) of women with ovarian
cancer are diagnosed in advanced stages,1 2
with a median survival of approximately
2 years,3 and we may therefore overlook
important factors for survival by primarily
focusing on long-term survival. Ovarian
cancer has a high mortality,4 and we need to
focus on additional areas of prognostic
importance in order to improve the outcome.
Previous studies of the survival of women
with ovarian cancer have focused on mortal-
ity within the ﬁrst 30–60 days after surgery or
on long-term survival. These studies have
identiﬁed commonplace predictors of mor-
tality (ie, complications to surgery, FIGO
stage and residual tumour tissue5). To the
best of our knowledge, no former studies
have focused on predictors of mortality
within 1 year after primary ovarian cancer
surgery. However, we hypothesised that ana-
lysing the intermediate survival of women
(up to 1 year after surgery) would provide
valuable information on potentially signiﬁ-
cant factors for survival. If this hypothesis
proves correct, these factors should be con-
sidered in the perioperative settings and are
useful in the counselling of the patient.
Using data from the nationwide Danish
Gynaecology Cancer Database (DGCD)
Strengths and limitations of this study
▪ This is a population-based study on 2654
women with prospective registered data.
▪ We used data sources of high quality and there
was no loss to follow-up.
▪ Adjustment for multiple factors was made: age,
preoperative health score, body mass index,
International Federation of Gynaecology and
Obstetrics (FIGO) stage, residual tumour tissue
after surgery, perioperative blood transfusion.
▪ We were unable to perform analyses regarding
neoadjuvant chemotherapy prior to surgery.
▪ There were missing data on smoking, alcohol,
laboratory data and specific cause of death.
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obtained from 2005 to 2012, and the Danish Civil
Registration System (CPR registry), the aims were to
examine predictors of mortality within 0–180 and 181–
360 days after primary ovarian cancer surgery. The exam-
ined predictors of mortality were age, preoperative
American Society of Anaesthesiologists (ASA) score,6
smoking, body mass index (BMI), International
Federation of Gynaecology and Obstetrics (FIGO) stage,
residual tumour tissue after surgery, perioperative blood
transfusion and calendar year of surgery.
MATERIALS AND METHODS
Study population
The study includes all Danish women who had under-
gone primary ovarian cancer surgery performed from 1
January 2005 to 31 December 2012 and who were identi-
ﬁed in the DGCD. The DGCD is a national clinical data-
base established on 1 January 2005,7 and since then all
patients with a ﬁrst-time diagnosis of ovarian cancer
have been prospectively registered. This was based on
mandatory reports from all Danish departments of
gynaecology and histopathology. The DGCD contains
details about preoperative patient characteristics (ie,
age, ASA score, smoking and BMI), perioperative infor-
mation (ie, FIGO stage, residual tumour tissue after
surgery, blood transfusion, etc) and postoperative details
(ie, histopathology, ﬁnal tumour stage veriﬁcation, com-
plications and adjuvant chemotherapy).
The ovarian cancer data in the DGCD have previ-
ously been validated and the registry was concluded to
be valuable for quality monitoring in gynaecological
oncology.8 Each patient is identiﬁed by a unique
10-digit number given to all Danish citizens by the
CPR registry at birth or when residence permits are
obtained.9
The DGCD included 2831 women who had primary
ovarian cancer surgery during the study period. The fol-
lowing were exclusion criteria: (1) a preoperative ASA
score obtained >6 months before surgery (n=119), pre-
suming 6 months to be the maximum time period to
surgery if neoadjuvant chemotherapy had been admini-
strated, and (2) a histopathology requisition completed
later than 2 weeks after surgery (n=58), signifying that
the speciﬁc pathology requisition most certainly origi-
nates from the current surgery. The CPR registry pro-
vided information on overall survival.
Data on predictive variables
From the DGCD, we speciﬁcally obtained data on age at
the time of surgery, preoperative ASA score6 (indicating
comorbidity at the time of surgery), preoperative BMI,10
preoperative smoking habits, FIGO stage,11 size of
residual tumour tissue after surgery (visually evaluated
by the surgeon at the end of surgery), perioperative
blood transfusion and calendar year of surgery. We also
received data on alcohol consumption, but due to
several missing pieces of data, this parameter was
omitted from further analyses. All the aforementioned
parameters, apart from alcohol, were evaluated as pre-
dictors of mortality.
Age: The women were divided into two groups accord-
ing to the median age: (1) age ≤64 years and (2) age
>64 years at the time of surgery.
ASA score: All women were divided into two groups by
the anaesthetists depending on the preoperative ASA
score: (1) ASA score=1 (without comorbidity) and (2)
ASA score >1 (with comorbidity).
Smoking: At the preoperative interview, women were
divided into two groups according to the current
smoking status: (1) non-smokers and (2) smokers.
BMI: Usually, BMI is divided into the following groups:
underweight, normal, overweight and obese, but in our
study population only a small group of women had
BMI≥30 kg/m2. Therefore, all women were assigned into
three groups according to BMI: (1) BMI<18.5 kg/m2
(underweight), (2) BMI 18.5–25 kg/m2 (normal) and
(3) BMI>25 kg/m2 (overweight).
FIGO stage: The women were divided into two groups:
(1) FIGO stages I and II (localised disease), and (2)
FIGO stages III and IV (advanced disease).
Residual tumour: The size of the residual tumour was
evaluated by the surgeon at the end of surgery, thereby
forming three groups: (1) no residual tumour, (2)
residual tumour ≤2 cm and (3) residual tumour >2 cm.
Blood transfusion: The women were grouped in two
ways: (1) those who did not receive perioperative blood
transfusion and (2) those who did.
Statistical analysis
The overall survival was illustrated by Kaplan-Meier plots
of each of the following variables: age (≤64 and
>64 years), ASA score (1 and >1), smoking (no, yes), BMI
(underweight, normal, overweight), FIGO stage (loca-
lised, advanced), residual tumour tissue after surgery
(none, ≤2 and >2 cm) and perioperative blood transfusion
(no, yes). Predictive variables of interests were assessed
descriptively according to death within 0–180 and 181–
360 days after surgery. To estimate the time-varying
effect of the predictive variables on survival within the
two time periods (0–180 and 181–360 days after
surgery), we used an extended Cox model.12 Included
variables followed the aforementioned categorisation,
and the calendar year of surgery was included as a con-
tinuous variable. Since missing data concerning smoking
were observed not to be random, the estimates obtained
for this variable may be biased. Accordingly, if there is
any interaction between this variable and other covari-
ates, estimates of other covariates may also be biased.
Omitting smoking from the model did not substantially
change the estimates of the other variables, and thus the
ﬁnal model was reduced on the basis of the results of
the Wald tests. The ﬁnal model included the following
variables: age, ASA score, BMI, FIGO stage, residual tumour
tissue after surgery, perioperative blood transfusion and calen-
dar year. After applying the model, we tested whether
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there is a signiﬁcant difference for each predictor vari-
able between the two time periods by performing a
Wald test. The results of the extended Cox model were
reported by the HR and 95% CIs and the Wald test with
the p values.
All analyses were conducted using Stata V.12 software
(StataCorp LP, College Station, Texas, USA).
According to Danish law, ethical approval and patient
consent are not required for purely registry-based
studies.
RESULTS
Our study included 2654 women who underwent
surgery after a diagnosis of primary ovarian cancer from
1 January 2005 to 31 December 2012. The majority of
these women were characterised by age ≤64 years
(52%), preoperative ASA score >1 (61%), normal BMI
(52%), advanced FIGO stage (63%), radical surgery
(68%) and no perioperative blood transfusion (75%;
table 1). The overall 1-year survival was 84%. A total of
412 women (16%) died within the ﬁrst postoperative
year. Women who died after surgery (both within 0–180
and 181–360 days) were predominantly characterised by
age >64 years, ASA score >1 and advanced FIGO stage.
For further descriptive details, see table 1.
Survival
The Kaplan-Meier ﬁgures show the separate effect of
the included predictive variables on survival up to
360 days after surgery (ﬁgure 1). The ﬁgures illustrate a
decreased survival in women >64 years compared with
women ≤64 years, in women with ASA score >1 com-
pared with ASA=1, in underweight women compared
with overweight and normal weight women, in women
with advanced FIGO stage compared with localised
FIGO stage, in women with >2 cm residual tumour tissue
left at surgery compared with ≤2 cm and no residual
tumour tissue, respectively, and in women who received
perioperative blood transfusion in comparison to no
transfusion.
Predictors on mortality
Table 2 shows the results of the multivariable Cox regres-
sion analysis and the included variables were thus mutu-
ally adjusted in the model. Age >64 years had a
statistically signiﬁcant negative impact on mortality both
within 0–180 and 181–360 days after surgery. Using age
as a continuous variable did not change the effect of the
other variables. ASA score ≥1 had a statistically signiﬁ-
cant negative impact on mortality only within 0–180 days
after surgery. The magnitude of the effect of ASA score
≥1 decreased signiﬁcantly during time with HR=2.17
(95% CI 1.46 to 3.23) within 0–180 days after surgery to
HR=1.25 (95% CI 0.88 to 1.76) within 181–360 days.
Being underweight increased mortality in both time
periods compared with normal weighted women with
HR=2.01 (95% CI 1.29 to 3.07) and HR=2.08 (95% CI
1.18 to 3.66) within 0–180 and 181–360 days after
surgery, respectively. Advanced FIGO stage only had a
statistically signiﬁcant effect within 181–360 days after
surgery (HR=2.81 (95% CI 1.75 to 4.50)). Residual
tumour ≤2 and >2 cm signiﬁcantly decreased survival in
both time periods after surgery, with the most pro-
nounced effect for residual tumour >2 cm within 0–
180 days after surgery (HR=4.58 (95% CI 3.20 to 6.59)).
The impact of residual tumour >2 cm was still present
after 6 months. Perioperative blood transfusion signiﬁ-
cantly increased mortality in the period 0–180 days after
surgery (HR=1.62 (95% CI 1.21 to 2.16)). In the model,
calendar year of surgery did not affect mortality, but it
was nearly signiﬁcant within the ﬁrst 6 months.
Some interaction exists between residual tumour and
FIGO stage, but this did not change the overall conclusions.
DISCUSSION
Predictors of the ovarian cancer mortality within the
ﬁrst year after surgery have not been intensively investi-
gated. However, focusing only on the perioperative mor-
tality and the 5-year survival may result in overlooking
factors important for the survival of the patient. This
study examined predictors of mortality within 0–180 and
181–360 days after primary ovarian cancer surgery.
Within 0–180 days after surgery, the three most import-
ant predictors of mortality were residual tumour >2 cm,
followed by residual tumour ≤2 cm and age >64 years.
Within 181–360 days after surgery, advanced FIGO stage,
underweight and residual tumour tissue >2 cm were the
three most important predictors of mortality. Less
important, but still statistically signiﬁcant predictors of
survival in the ﬁrst 6 months after surgery, were ASA>1
and perioperative blood transfusion. Underweight
women had a signiﬁcantly increased mortality within the
ﬁrst postoperative year.
Our study has several strengths; it is based on nation-
wide prospective registered data, it includes several
important predictive variables for mortality and no
women were lost at follow-up due to complete informa-
tion during the entire study period. The validity of data
in the DGCD is essential for our results, and the data-
base has previously been successfully validated on
primary epithelial ovarian cancer by a comparison of the
surgical and histopathological data in the registry with
the corresponding medical ﬁle and the National
Registry of Patients as reference.8
We observed that residual tumour tissue (both <2 and
>2 cm) left at surgery has a statistically signiﬁcant nega-
tive effect on survival in both periods after surgery. This
ﬁnding has been outlined in many other studies,13–15
but our results indicate that a residual tumour of >2 cm
is the most important predictor of death within the ﬁrst
6 months after surgery. The present results and other
studies unambiguously identify macroscopic tumour
tissue resection as an important surgical issue in improv-
ing survival.16–18
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We were unable to identify women treated with neoad-
juvant chemotherapy prior to surgery due to absent data
throughout the entire study period. Since preoperative
neoadjuvant chemotherapy is mainly administered to
women with advanced FIGO stages, in combination with
the possible underestimation of residual tumour tissue
at surgery following neoadjuvant chemotherapy,15 our
results may be underestimated due to the possible blend
of women with different characteristics. However, since
neoadjuvant chemotherapy is only administered at
advanced FIGO stages, it is unlikely that our strongest
predictor of mortality (residual tumour tissue) within
1 year after surgery is biased, and our main conclusion
of this study remains unchanged.
We also observed advanced FIGO stage to be an
important predictor of mortality, but mainly within 181–
360 days after surgery. The negative impact of advanced
FIGO stage on mortality is well known and has been
described in other investigations,16–18 but the negative
effect on mortality within the ﬁrst year after surgery has
not been reported previously. We observed underweight
to be a predictor of mortality both 0–180 and 181–
360 days after surgery. In contrast, Skírnisdóttir and
Sorbe19 concluded that BMI did not inﬂuence survival
when evaluating women with low-stage ovarian cancer.
As in our study, Skírnisdóttir and Sorbe used the BMI
reported at the time of surgery, but they did not evaluate
its inﬂuence on survival until 19–214 months later.
Therefore, for the ﬁrst time, we report the negative
effect of being underweight on mortality within the ﬁrst
postoperative year. Malnutrition and ascites are well-
known problems among patients with ovarian
cancer.20 21 Owing to the frequent concomitant pres-
ence of ascites, the real preoperative BMI may be lower
Table 1 Descriptive characteristics according to death up to 360 days after primary ovarian cancer surgery in Danish women










at least 361 days after
surgery
All women 2654 (100) 226 (9) 186 (7) 2242 (84)
Age*
≤64 years (%) 1380 (52) 53 (4) 75 (5) 1252 (91)
>64 years (%) 1274 (48) 173 (14) 111 (9) 990 (78)
ASA
Score 1 (%) 1023 (39) 33 (3) 52 (5) 938 (92)
Score >1 (%) 1622 (61) 192 (12) 133 (8) 1297 (80)
Missing (%) 9 (0) 1 (11) 1 (11) 7 (78)
Smoking
No (%) 1306 (49) 95 (7) 86 (7) 1125 (86)
Yes (%) 1046 (39) 89 (9) 74 (7) 883 (84)
Missing (%) 302 (11) 42 (14) 26 (9) 234 (77)
BMI
Underweight (%) 117 (4) 24 (20) 17 (15) 76 (65)
Normal (%) 1369 (52) 122 (9) 91 (7) 1156 (84)
Overweight (%) 1095 (41) 72 (6) 74 (7) 949 (87)
Missing (%) 73 (3) 8 (11) 4 (5) 61 (84)
FIGO stage
Localised (%) 965 (36) 34 (4) 24 (2) 907 (94)
Advanced (%) 1668 (63) 190 (11) 161 (10) 1317 (79)
Missing (%) 21 (1) 2 (10) 1 (5) 18 (85)
Residual tumour
None (%) 1798 (68) 65 (4) 86 (5) 1647 (91)
≤2 cm (%) 328 (12) 45 (14) 36 (11) 247 (75)
>2 cm (%) 519 (20) 115 (22) 63 (12) 341 (66)
Missing (%) 9 (0) 1 (11) 1 (11) 7 (78)
Blood transfusion
No (%) 2000 (75) 143 (7) 125 (6) 1732 (87)
Yes (%) 648 (24) 83 (13) 60 (9) 505 (78)
Missing (%) 6 (0) 0 (0) 1 (17) 5 (83)
Calendar year
2005–2006 764 (29) 81 (11) 53 (7) 630 (82)
2007–2009 1073 (40) 99 (9) 79 (7) 895 (84)
2010–2012 817 (31) 46 (6) 54 (6) 717 (88)
*Age was divided into two groups according to the median age.
ASA, American Society of Anesthesiologists; BMI, body mass index; FIGO, International Federation of Gynaecology and Obstetrics.
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than measured and the negative inﬂuence exerted by
underweight is thereby underestimated in our analyses.
In a recent study, Ataseven et al22 observed low
preoperative albumin to be an independent predictor
for severe postoperative complications, and to be inde-
pendently associated with reduced overall survival. We
Figure 1 The Kaplan-Meier survival estimates on possible predictive variables in Danish women within the first year after
primary ovarian cancer surgery (2005–2012), with the X-axis indicating days after surgery and the Y-axis indicating the survival
proportion in percentage. ASA, American Society of Anesthesiologists; BMI, body mass index; FIGO, International Federation of
Gynaecology and Obstetrics.
Table 2 Results from the Cox multivariable regression analyses estimating the impact of possible predictive variables on








p Values for test for
homogeneity between
the two time periods
Age*
(>64 vs ≤64 years) 2.33 (1.69 to 3.21) 1.64 (1.19 to 2.25) 0.1240
ASA score
(>1 vs 1) 2.17 (1.46 to 3.23) 1.25 (0.88 to 1.76) 0.0383
BMI
(Underweight vs normal) 2.01 (1.29 to 3.07) 2.08 (1.18 to 3.66) 0.9046
(Overweight vs normal) 0.82 (0.61 to 1.11) 1.08 (0.79 to 1.48) 0.2093
Residual tumour
(≤2 cm vs none) 2.50 (1.63 to 3.82) 1.68 (1.11 to 2.53) 0.1863
(>2 cm vs none) 4.58 (3.20 to 6.59) 1.84 (1.25 to 2.70) 0.0007
FIGO stage
(Advanced vs localised) 1.28 (0.83 to 1.96) 2.81 (1.75 to 4.50) 0.0151
Blood transfusion
(Yes vs no) 1.62 (1.21 to 2.16) 1.28 (0.92 to 1.78) 0.2912
Calendar year
(Increasing) 0.86 (0.72 to 1.04) 0.99 (0.81 to 1.21) 0.3076
Data are reported by HR, 95% CIs, and the results of the time interval heterogeneity test are reported by p values.
All HRs were mutually adjusted for the other variables.
*Age was divided into two groups according to the median age.
ASA, American Society of Anesthesiologists; BMI, body mass index; FIGO, International Federation of Gynaecology and Obstetrics.
Ørskov M, et al. BMJ Open 2016;6:e010123. doi:10.1136/bmjopen-2015-010123 5
Open Access
group.bmj.com on March 23, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
did not have information of serum albumin, which
could have qualiﬁed the measurement of nutritional
status. Body composition CT scan may even be superior
to serum albumin when nutritional status prior to
surgery is evaluated, as low subcutaneous fat as well as
low muscular fat both have been shown to be independ-
ent predictors of mortality.23 We did not, however, have
any such measures.
In our study, women >64 years demonstrated poorer
survival in comparison to women ≤64 years in the ﬁrst
year after surgery, with the most pronounced impact of
older age on mortality observed 0–180 days after surgery
and thereafter exceeded by more important factors. In
several countries, the relative 1-year and 5-year survival
of women diagnosed with ovarian cancer have previously
been reported to decrease with old age.24–26 However, to
the best of our knowledge, the fact that the impact of
old age occurs mainly in the ﬁrst period after surgery is
new information. Jørgensen et al,27 Trillsch et al28 and
Sabatier et al29 noted that old women with ovarian
cancer may demonstrate worse survival due to poten-
tially inferior treatment, but our data do not include
information to illuminate this aspect.
We found comorbidity (ASA>1) as a predictor of mor-
tality, but only at 0–180 days after surgery, and with a
decreasing importance over time. Grann et al30 and
Sperling et al31 also observed comorbidity to be a pre-
dictor of mortality. However, in contrast to our results,
they did not evaluate the effect on the immediate post-
operative time period, but evaluated data after 1 year
(Grann et al30 and Sperling et al31) and 5 years (Grann
et al30). Consequently, our data also offer new informa-
tion in this ﬁeld and may indicate that reduction of any
pre-existing comorbidity could be important in the
increasing survival after primary ovarian cancer surgery.
Perioperative blood transfusion was observed to be a
predictor of mortality 0–180 days after surgery. This is a
new ﬁnding in women with ovarian cancer, but a negative
effect of blood transfusion on survival has been described
in other diseases.32 33 Among patients with gynaeco-
logical cancer, transfusion has been described to be asso-
ciated with higher morbidity and increased mortality
within the immediate 30 days after surgery, when control-
ling for parameters such as age, comorbidity, pre-existing
anaemia, type of surgery, etc.34 Immune modulatory
mechanisms are suggested to induce the aforementioned
complications.35 Since the DGCD does not contain infor-
mation on haemoglobin levels or total transfused blood
units, we were unable to evaluate any possible inﬂuence
of these parameters. Our ﬁndings might indicate that
perioperative blood transfusion should only be pre-
scribed to a very restricted group of patients, although
this aspect needs to be studied in more detail.
Our study also has limitations. According to the incident
numbers of Danish patients with ovarian cancer (2005–
2012),36 a total of 86–92% had primary ovarian cancer
surgery performed;7 however, only 67% of the operated
patients were eligible for evaluation in our study. Missing
information on smoking and alcohol prevented examin-
ation of the impact on survival. As discussed previously,
analyses regarding neoadjuvant chemotherapy prior to
surgery were not available due to absent information of
this parameter throughout the entire study period. In add-
ition, information regarding laboratory data would have
been valuable. Other causes of death than ovarian cancer
increase with age and the use of overall survival may have
caused confounding. However, information on the causes
of death was not available.
Residual tumour tissue, advanced FIGO stage, being
underweight, comorbidity and perioperative blood trans-
fusion were all found to be predictors of mortality
within the ﬁrst year after primary ovarian cancer surgery.
Our results suggest that the surgeon should not just aim
at radical surgery, but also pay attention to comorbidity,
nutritional state and the use of perioperative blood
transfusion. These ﬁndings should be conﬁrmed in
other settings, and future studies are needed to assess
the impact of smoking, alcohol, units of blood trans-
fused and neoadjuvant chemotherapy as predictors of
mortality within the ﬁrst postoperative year after primary
ovarian cancer surgery.
CONCLUSIONS
In this study, we aimed to examine predictors of mortal-
ity within 0–180 and 181–360 days after ovarian cancer
surgery. The examined predictors were age, ASA score,
BMI, FIGO stage, residual tumour tissue after surgery,
perioperative blood transfusion and calendar year of
surgery. The overall 1-year survival was 84%. The most
important predictors of mortality within 1 year after
surgery were residual tumour tissue (0–180 days after
surgery) and advanced FIGO stage (181–360 days after
surgery). Our results suggest that the surgeon should
aim at radical surgery. However, comorbidity, being
underweight, age >64 years and blood transfusion were
also signiﬁcant predictors of mortality and need to be
studied in more detail.
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